Your session is about to expire
← Back to Search
Neurostimulation
Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot
N/A
Waitlist Available
Research Sponsored by HealthTech Connex Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 6
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new approach that combines gentle electrical stimulation on the tongue with talk therapy to help people with PTSD. The goal is to see if this combination makes the therapy more effective by helping the brain become more adaptable.
Eligible Conditions
- PTSD
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to week 6
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 6
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Clinician-rated symptom severity as measured by CAPS
Ease of protocol administration
Participant rated symptom severity as measured by the PCL-5
+3 moreSecondary study objectives
Brief Inventory of Psychosocial Functioning (B-IPF)
Electroencephalography (EEG)
Generalized Anxiety Disorder 7-item (GAD-7)
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: TLNSExperimental Treatment1 Intervention
Translingual neurostimulation will be paired with breathing and awareness training prior to CPT sessions
Group II: ControlActive Control1 Intervention
No TLNS
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Translingual neurostimulation
2021
N/A
~10
Find a Location
Who is running the clinical trial?
Centre for Neurology StudiesUNKNOWN
HealthTech Connex Inc.Lead Sponsor
5 Previous Clinical Trials
978 Total Patients Enrolled